R&D Trends

IBM Watson Health, Broad Institute launch research initiative

Friday, November 11, 2016

IBM Watson Health and the Broad Institute of MIT and Harvard have announced a research initiative aimed at discovering the basis of cancer drug resistance. The five year, $50 million project will study thousands of drug resistant tumors and draw on Watson’s computational and machine learning methods to help researchers understand how cancers become resistant to therapies. The anonymized data will be made available to the scientific community to catalyze research worldwide.

[Read More]

INC Research to manage Leukemia & Lymphoma Society umbrella trial

Friday, November 11, 2016

INC Research, a global phase I to IV CRO, has announced its involvement in The Leukemia & Lymphoma Society’s (LLS) recently-launched precision medicine Master Trial to treat acute myeloid leukemia (AML). The Beat AML Master Trial is breaking ground in a number of areas, including the first time a nonprofit organization is working with multiple biotech and pharma sponsors and other key collaborators to professionally operationalize a study. The trial will provide principal investigators and their patients consolidated access to test novel therapies matched to specific molecular aberrations in AML.

[Read More]

Evotec and Oxford create novel LAB282 partnership

Thursday, November 10, 2016

Evotec has announced a novel strategic partnership with the University of Oxford, the university’s research commercialization company Oxford University Innovation (OUI) and Oxford Sciences Innovation, an IP investment company dedicated to a single university (OSI) aimed at accelerating the translation of basic biomedical research from Oxford into new therapeutics. Projects will be sourced exclusively from Oxford University researchers via OUI across any therapeutic area and for any therapeutic modality and will be aided by a drug discovery expert in residence seconded by Evotec to the LAB282 initiative and embedded in the university.

[Read More]

Symcel, TiKa Diagnostics and St. George’s partner

Wednesday, November 9, 2016

Symcel, the company behind a cell-based assay tool for real-time cellular bioenergetic measurements, calScreener, has partnered with TiKa Diagnostics and St. George’s University of London for the use of its microcalorimetry technology in testing mycobacteria and for antimicrobial peptide (AMP) studies. The rapid detection of antimicrobial resistance is now crucial to maximize efforts in controlling the prevalence and spread of drug resistant Mycobacterium tuberculosis (Mtb). Moreover, the development of novel agents, such as AMPs, able to combat superbugs and interfere with biofilm formation, has become a key necessity.  

[Read More]

Harris awarded $43M follow-on contract by NCI

Monday, November 7, 2016

Harris has been awarded a 5-year, $43 million follow-on contract by the National Cancer Institute‘s Center for Cancer Research, continuing a legacy of providing comprehensive clinical data management for the Institute’s intramural clinical trials program. The contract, which includes one base year and four one-year options, was awarded during the first quarter of Harris’ fiscal 2017.

[Read More]

Envigo launches hepatotoxicity testing for drug development de-risking program

Monday, November 7, 2016

Envigo has launched an integrated program of in vitro technologies that help predict the likelihood of compounds causing drug induced livery injury (DILI)—one of the major causes of drugs being withdrawn from the market. Since 1980, over 30 drugs have been withdrawn because of hepatotoxicity with many others having severe restrictions placed upon their use. As a consequence, and to help minimize any risks to patients taking their medicines, the pharma industry is concerned not to progress compounds that show any potential DILI liability.

[Read More]

Flatiron Health, Foundation Medicine oncology clinico-genomic database

Friday, November 4, 2016

Flatiron Health and Foundation Medicine have announced the launch of a clinico-genomic database designed to help researchers and biopharmaceutical partners accelerate the development of targeted therapeutics and immunotherapies to treat cancer. The clinico-genomic database, containing information on nearly 20,000 patients, is one of the largest and most comprehensive information efforts of its kind in oncology.

[Read More]

Report: Nine evidence-based approaches to transform drug development and commercialization

Monday, October 31, 2016

Life sciences companies increasingly are seeking new models to connect expanding sets of disparate, non-identified patient-level data streams to better develop and commercialize next-generation medicines. The need for practical, evidence-based approaches is especially acute at a time when scientific advances, the growing need for new medicines, and constrained budgets for healthcare and other social services are colliding.

[Read More]